Impact of HLA class I functional divergence on HIV control
Mathias Viard, Colm Ó’hUigín, Yuko Yuki, Arman Bashirova, David R. Collins, Jonathan M. Urbach, Steven M. Wolinsky, Susan Buchbinder, Gregory D. Kirk, James J. Goedert, Nelson L. Michael, David W. Haas, Steven G. Deeks, Bruce D. Walker, Xu G. Yu, Mary Carrington
Abstract
Heterozygosity of Human leukocyte antigen ( HLA ) class I genes is linked to beneficial outcomes after HIV infection, presumably through greater breadth of HIV epitope presentation and cytotoxic T cell response. Distinct allotype pairs, however, differ in the extent to which they bind shared sets of peptides. We developed a functional divergence metric that measures pairwise complementarity of allotype-associated peptide binding profiles. Greater functional divergence for pairs of HLA-A and/or HLA-B allotypes was associated with slower AIDS progression and independently with enhanced viral load control. The metric predicts immune breadth at the peptide level rather than gene level and redefines HLA heterozygosity as a continuum differentially affecting disease outcome. Functional divergence may affect response to additional infections, vaccination, immunotherapy, and other diseases where HLA heterozygote advantage occurs.